We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Seagen Inc | NASDAQ:SGEN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 228.74 | 228.74 | 228.74 | 0 | 01:00:00 |
1. Name and Address of Reporting Person * BAKER BROS. ADVISORS LP | 2. Issuer Name and Ticker or Trading Symbol Seagen Inc. [ SGEN ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 11/30/2021 | S | 19226 | D | $160 | 4083862 | I | See Footnotes (1)(2)(3)(4)(5) | ||
Common Stock | 11/30/2021 | S | 208597 | D | $160 | 43100476 | I | See Footnotes (2)(3)(4)(5)(6) | ||
Common Stock | 11/30/2021 | S | 540 | D | $160.0757 (7) | 4083322 | I | See Footnotes (1)(2)(3)(4)(5) | ||
Common Stock | 11/30/2021 | S | 5860 | D | $160.0757 (7) | 43094616 | I | See Footnotes (2)(3)(4)(5)(6) | ||
Common Stock | 11/30/2021 | S | 2713 | D | $160.5270 (8) | 4080609 | I | See Footnotes (1)(2)(3)(4)(5) | ||
Common Stock | 11/30/2021 | S | 29432 | D | $160.5270 (8) | 43065184 | I | See Footnotes (2)(3)(4)(5)(6) | ||
Common Stock | 11/30/2021 | S | 1858 | D | $160.9599 (9) | 4078751 | I | See Footnotes (1)(2)(3)(4)(5) | ||
Common Stock | 11/30/2021 | S | 20154 | D | $160.9599 (9) | 43045030 | I | See Footnotes (2)(3)(4)(5)(6) | ||
Common Stock | 11/30/2021 | S | 123 | D | $163.3877 (10) | 4078628 | I | See Footnotes (1)(2)(3)(4)(5) | ||
Common Stock | 11/30/2021 | S | 1337 | D | $163.3877 (10) | 43043693 | I | See Footnotes (2)(3)(4)(5)(6) | ||
Common Stock | 11/30/2021 | S | 886 | D | $164.8228 (11) | 4077742 | I | See Footnotes (1)(2)(3)(4)(5) | ||
Common Stock | 11/30/2021 | S | 9618 | D | $164.8228 (11) | 43034075 | I | See Footnotes (2)(3)(4)(5)(6) | ||
Common Stock | 11/30/2021 | S | 93 | D | $165.6841 (12) | 4077649 | I | See Footnotes (1)(2)(3)(4)(5) | ||
Common Stock | 11/30/2021 | S | 1007 | D | $165.6841 (12) | 43033068 | I | See Footnotes (2)(3)(4)(5)(6) | ||
Common Stock | 12/1/2021 | S | 2381 | D | $160.8032 (13) | 4075268 | I | See Footnotes (1)(2)(3)(4)(5) | ||
Common Stock | 12/1/2021 | S | 25833 | D | $160.8032 (13) | 43007235 | I | See Footnotes (2)(3)(4)(5)(6) | ||
Common Stock | 12/1/2021 | S | 768 | D | $161.3450 | 4074500 | I | See Footnotes (1)(2)(3)(4)(5) | ||
Common Stock | 12/1/2021 | S | 8332 | D | $161.3450 | 42998903 | I | See Footnotes (2)(3)(4)(5)(6) | ||
Common Stock | 12/1/2021 | S | 4738 | D | $161.3873 (14) | 4069762 | I | See Footnotes (1)(2)(3)(4)(5) | ||
Common Stock | 12/1/2021 | S | 51399 | D | $161.3873 (14) | 42947504 | I | See Footnotes (2)(3)(4)(5)(6) | ||
Common Stock | 23280 (15) | D | ||||||||
Common Stock | 23277 (16) | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Remarks: Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, the sole general partner of Baker Bros. Advisors LP, is a director of Seagen Inc. (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer. |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
BAKER BROS. ADVISORS LP 860 WASHINGTON STREET, 3RD FLOOR NEW YORK, NY 10014 | X | X | |||
667, L.P. 860 WASHINGTON STREET, 3RD FLOOR NEW YORK, NY 10014 | X | X | |||
Baker Bros. Advisors (GP) LLC 860 WASHINGTON STREET, 3RD FLOOR NEW YORK, NY 10014 | X | X | |||
BAKER FELIX 860 WASHINGTON STREET, 3RD FLOOR NEW YORK, NY 10014 | X | X | |||
BAKER JULIAN 860 WASHINGTON STREET, 3RD FLOOR NEW YORK, NY 10014 | X | X | |||
Baker Brothers Life Sciences LP 860 WASHINGTON STREET, 3RD FLOOR NEW YORK, NY 10014 | X | X |
Signatures | ||
Felix Baker By: /s/ Felix J. Baker | 12/2/2021 | |
**Signature of Reporting Person | Date | |
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing | 12/2/2021 | |
**Signature of Reporting Person | Date | |
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker Brothers Life Sciences, L.P., Name: Scott L. Lessing, Title: President | 12/2/2021 | |
**Signature of Reporting Person | Date | |
By: BAKER BROS. ADVISORS LP By: /s/ By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing | 12/2/2021 | |
**Signature of Reporting Person | Date | |
By: Baker Bros. Advisors (GP) LLC By: /s/ By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing | 12/2/2021 | |
**Signature of Reporting Person | Date | |
Julian Baker By: /s/ Julian C. Baker | 12/2/2021 | |
**Signature of Reporting Person | Date |
1 Year Seagen Chart |
1 Month Seagen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions